Looking back over 2022, it’s been quite the year. Verantos was invited to present and moderate panels on high-validity RWE at all the leading industry conferences, including DIA, ISPOR, BIO, and AMIA. We launched the Verantos Evidence Platform, continued our work for the FDA demonstration project (TRUST), announced breakthroughs in high-validity RWE in NASH and migraine, and were named to the 2022 Inc 5000.

Heading into the holiday season, Verantos remains active. Lundbeck and Verantos published a manuscript on migraine, defining techniques to enable high-validity observational research and pragmatic registries. DIA featured Verantos in its November issue of Global Forum, sharing our perspective on how high-validity real-world evidence will ensure future patients receive optimized and tailored treatment.

Company News


Lundbeck and Verantos publish manuscript on an AI-based approach to understand migraine outcomes from routinely collected data

Study findings discuss the feasibility of developing artificial intelligence models for determination of soft outcomes such as migraine severity using the data elements typically captured in the real-world clinical setting. These models provide a scalable approach to high-validity migraine observational research and pragmatic registries.

Strength in Numbers: Distilling RWE into clinical practice

As part of DIA’s Global Forum November issue, Verantos sat down with DIA to discuss the need for improved real-world evidence, how Verantos is enabling high-validity real-world evidence at scale, and what that means for regulators, payers, prescribers, and patients.

Want to receive this newsletter in your inbox?